


Patient Name: XXXXXXXXXXX, XXXXX
Date of Birth: XX/XX/XX
Oncotech ID No: XXXXXXXXXXX
Institution: XXXXXXXXXXXXXXXXXXXX
Oncologist: XXXXXXXXXXXXXXXXXXXX
Surgeon: XXXXXXXXXXXXXXXXXXXX
Pathologist: XXXXXXXXXXXXXXXXXXXX
Medical Record: XXXXXXXXXXXXX
Pathology Ref. No: XXXXXXXX

Diagnosis: Non-Small Cell Lung Cancer
Prior Chemotherapy: No
Specimen Site: Lung
Specimen Size: 1.5 GM
Collection Date: XX/XX/XXXX
Date Received: XX/XX/XXXX
Date Reported: XX/XX/XXXX
Date Printed: XX/XX/XXXX
Report Page No: 1

DRUG RESISTANCE ASSAY

TEST CODE 100



The graph above represents relative tumor cell proliferation observed in the presence of each drug tested. Longer bars indicate greater in vitro proliferation and therefore greater resistance to a particular drug. Literature response rate is determined from an extensive review of clinical trials. Assay predicted response probability derives from an algorithm involving in vitro tumor cell proliferation, literature response rate, and patient treatment status, in accordance with the Bayesian mathematical model.

The Oncotech EDR Assay is a drug resistance assay. Use of the Oncotech EDR Assay to identify and/or select clinically active agents is not recommended.

This test was developed and its performance characteristics determined by Oncotech, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Prognostic and Predictive Marker Report


Patient Name: XXXXXXXXXXX, XXXXX	Diagnosis: Non-Small Cell Lung Cancer
Date of Birth: XX/XX/XX	Prior Chemotherapy: No
Oncotech ID No: XXXXXXXXXXX	Specimen Site: Lung
Institution: XXXXXXXXXXXXXXXXXXXX	Specimen Size: 1.5 GM
Oncologist: XXXXXXXXXXXXXXXXXXXX	Collection Date: XX/XX/XXXX
Surgeon: XXXXXXXXXXXXXXXXXXXX	Date Received: XX/XX/XXXX
Pathologist: XXXXXXXXXXXXXXXXXXXX	Date Reported: XX/XX/XXXX
Medical Record: XXXXXXXXXXXXX	Date Printed: XX/XX/XXXX
Pathology Ref. No: XXXXXXX	Report Page No: 1

DNA Test Results and Histogram

Relative Risk Assessment

Test Code	DNA Study	DNA Result	Favorable	Intermediate	Unfavorable
400	DNA Ploidy DNA Index S-Phase Fraction	Aneuploid 1.8 4.3%	Diploid 1.0 See Note	N/A - See Note	Aneuploid >1.0 or <1.0 See Note

NOTE: Percent S-phase fraction is associated with proliferative activity, however, the prognostic significance of the S-phase fraction in this tumor is still unknown at this time, and therefore, reference ranges are not available.



Interpretational Guidelines for DNA

Patients with aneuploid tumors have been shown to have a shorter disease-free survival period than patients with diploid tumors. Percent S-phase fraction is an additional prognostic marker and patients with elevated S-phase have increased probability of relapse. DNA content analysis has not yet been established as a diagnostic procedure and should be used only in conjunction with medically established tests and diagnostic procedures.

Note: Green peak denotes Diploid GoG1.

Test Results

Relative Risk Assessment

Test Code	Marker	% Cells +	Staining Intensity	Results / Histoscore	Favorable	Intermediate	Unfavorable
520	p53 Gene Product	0%	0+	0	Not Detected	Not Established	Detected
521	p21	0%	0+	Not Detected	Detected	Not Established	Not Detected
560	EGFR	30%	3+	Detected	Not Detected	Not Established	Detected
570	BCL-2 <small>Deregulated expression of bcl-2 proto-oncoprotein can render tumor cells resistant to certain chemotherapeutic agents. The presence of the bcl-2 proto-oncoprotein in certain tumors is associated with favorable prognosis. Bcl-2 proto-oncoprotein has not been established as a diagnostic procedure and therefore, should be used only in conjunction with other medically established tests and diagnostic procedures.</small>	0%	0+	Not Detected	Detected	Not Established	Not Detected
581	VEGF <small>Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a secreted heparin binding cytokine expressed in tumor. VEGF plays an important role in angiogenesis which promotes tumor progression and metastasis.</small>	30%	1+	Detected	Not Detected	Not Established	Detected
585	GST PI <small>GST-pi is a cytosolic enzyme which catalyzes the conjugation of toxic compounds to glutathione for transport out of the cell. Increased expression of GST-pi has been demonstrated to show increased resistance to alkylating agents such as cyclophosphamide, ifosphamide, and melphalan.</small>	30%	3+	Detected	Not Detected	Not Established	Detected

These tests were developed and their performance characteristics determined by Oncotech, Inc. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendment of 1988 (CLIA) as qualified to perform high complexity testing.